Anticoagulants Market Size to Reach $45.50 Billion by 2026; Applications in Treatment of Severe Cardiovascular Disease to Aid Growth

The global anticoagulants market size is projected to reach USD 45.50 billion by the end of 2026. According to a report published by Fortune Business Insights, titled “Anticoagulants Market Size, Share & Industry Analysis, By Disease Indication (Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT), Atrial Fibrillation, Heart Attacks, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2019-2026,” the market was worth USD 21.45 billion in 2018 and will exhibit a CAGR of 9.9% during the forecast period, 2019-2026.

High Product Efficiency Will Lead to a Subsequent Rise in it Demand in Several Healthcare Procedures across the World

Anticoagulants are substances that are used to manage blood clots. They help avoid lump formations in the blood and stop them from turning into solids. The increasing prevalence of cardiovascular diseases has opened up a wide potential for the use of anticoagulants. The rising incidence of heart-related disorders, including coronary heart diseases, hyperlipidemia, and hypertension. The high risks associated with cardiovascular diseases have created a huge emphasis on the treatment of the disease. According to the World Health Organization, 4 out every 5 cardiovascular diseases end in death due to heart strokes. Generally, cardiovascular diseases are treated by drugs that comprise of anticoagulants. The efficiency of anticoagulants in the treatment of cardiovascular diseases have led to a high adoption for the product across the world.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/anticoagulants-market-101807

Key Segments in the Anticoagulants Market:

• By Disease Indication: The market has been classified on the basis of disease indication into pulmonary embolism (PE). Deep vein thrombosis, atrial fibrillation, and heart attacks. Among these, the pulmonary embolism segment is projected to hold a dominant blood thinner market share in the coming years. Eliquis is one of the most widely adopted anticoagulant and it is specifically designed for the treatment of pulmonary embolism. The severity of this condition has drawn severe attention from healthcare analysts across the world. Unattended PE can block the flow of blood completely. PE can also result in life threatening conditions, as a result of which it will gain huge attention. The increasing investment in the treatment of PE will have a direct impact on the growth of this segment.  The deep vein thrombosis is another segment that is projected to witness considerable growth in the coming years due to the increasing cases of obesity and heart failures. As of 2018, the deep vein thrombosis (DVT) segment accounted for 17.3% of the overall anticoagulants market share.


• By Route of Administration: On the basis of route of administration, the market is segmented into oral and injectable. The oral segment is likely to emerge dominating in the coming years driven by the increasing number of product launches. The injectable segment will derive growth from the massive production and distribution of warfarin. It is one of the most commonly used injectable product, aimed at the treatment of blood disorders.


• By Distribution Channel: The market is segmented based on distribution channel into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital segment will hold a dominant market share, owing to the high risks associated with the use of anticoagulants in clinics. Generally, anticoagulants are prescribed after a thorough diagnosis that is normally conducted in hospitals.


• By Region: The market is segmented based on regional demographics into North America, Latin America, Asia Pacific, Europe, and the Middle East and Africa. Among these regions, the market in North America is likely to emerge leading owing to the high prevalence of cardiovascular diseases. Increasing emphasis on research and development activities will contribute to the growth of the market in this region. As of 2018, the market in North America was worth USD 10.10 billion and this value will increase further driven by the advancements in manufacturing of anticoagulants across this region.

Key Players to Gain Dominance Owing to their Robust Product Portfolio and Geographical Presence

Companies such as Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc., and Pfizer Inc., are expected to emerge dominant in the global anticoagulants market. This is attributable to their strong product portfolio, wide geographical presence, and adoption of strategies. In addition to this, companies are planning to put huge efforts to stay ahead out of competition.

Some of the leading companies that are operating in the global market are:

• Bristol-Myers Squibb Company


• Pfizer Inc.


• Bayer AG


• Janssen Pharmaceuticals, Inc.


• Eisai Co., Ltd.


• Other Prominent Players

Key Industry Developments:

• February 2019: Novartis AG and Blackstone’s Life Sciences announced the launch of Anthos Therapeutics, a company aiming at the development of new and pipeline drugs that are comprised of anticoagulants.

The global anticoagulants market is segmented on the basis of: